par Moreau, R;Chagneau, C;Heller, J;Chevenne, D;Langlet, Philippe 
;Deltenre, Pierre ;Hillaire, Sophie;Lefilliatre, P;Pateron, D;Sogni, P;Valla, Dominique;Lebrec, D
Référence Scandinavian journal of gastroenterology, 36, 3, page (303-308)
Publication Publié, 2001-03
;Deltenre, Pierre ;Hillaire, Sophie;Lefilliatre, P;Pateron, D;Sogni, P;Valla, Dominique;Lebrec, DRéférence Scandinavian journal of gastroenterology, 36, 3, page (303-308)
Publication Publié, 2001-03
Article révisé par les pairs
| Résumé : | In patients with cirrhosis, glucose may induce splanchnic and renal vasodilation. Since the antidiabetic sulfonylurea glibenclamide is known to induce splanchnic and renal vasoconstriction in portal hypertensive animals, this drug may inhibit glucose-induced hemodynamic responses in patients with cirrhosis. The aim of the present study was to investigate, in patients with cirrhosis, the short-term effects of glibenclamide on hemodynamic and humoral responses to glucose. |
